This study is currently not recruiting participants.

Risk-based response-adapted Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children adolescents and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation.

Study on Investigational Medication for Classic Hodgkin Lymphoma (CHL)

Not Recruiting
5 years - 30 years
All
Phase N/A

Brief description of study.

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL).

Detailed description of study

The purpose of this study is to test the effectiveness, safety, and tolerability of an investigational drug called nivolumab in children, adolescents, and young adults with classic Hodgkin Lymphoma (CHL) in combination with brentuximab vedotin.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hodgkin Disease
  • Age: 5 years - 30 years
  • Gender: All

This study investigates the safety and effectiveness of an investigational medication in combination with another treatment for patients with Hodgkin's lymphoma. Hodgkin's lymphoma is a type of cancer that affects the lymphatic system, which is part of the immune system. The study aims to find out how well these treatments work together in children, adolescents, and young adults.

Participants in this study will receive a combination of investigational medication and another treatment. If the response to this treatment is not optimal, an additional medication may be added. The study will monitor the safety and tolerability of these treatments in the participants.

  • Who can participate: Children, adolescents, and young adults with classic Hodgkin Lymphoma (CHL) may be eligible to participate in this study. The specific age range for participants is not provided.
  • Study details: Participants will receive nivolumab combined with brentuximab vedotin. In cases of suboptimal response, an additional medication may be included. A placebo is not used in this study.
Updated on 19 Feb 2024. Study ID: 1704198675 (PHO-BMS-FALLO

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team